title: siRNA nanotherapeutics: a Trojan horse approach against HIV.
abstract: The concept of RNA interference (RNAi) is gaining popularity for the better management of various diseases, including HIV. Currently, the successful biomedical utilization of siRNA therapeutics is hampered, both in vivo and in vitro, mainly by the inherent inability of naked siRNA to cross the cell membrane. RNAi can potentially improve the weakness of current highly active antiretroviral therapy (HAART) by diminishing the chances of the appearance of antiHIV-resistant strains. Here, we discuss the nanocarrier-mediated delivery of siRNA delivery as well as highlighted the scope of siRNA-mediated gene-silencing technology for improved HIV treatment.
authors.affiliation: Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr H.S. Gour Central University, Sagar, MP, India.
authors.forename: Vijay
authors.initials: V
authors.lastname: Mishra
authors.affiliation: Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr H.S. Gour Central University, Sagar, MP, India.
authors.forename: Prashant
authors.initials: P
authors.lastname: Kesharwani
authors.affiliation: Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr H.S. Gour Central University, Sagar, MP, India. Electronic address: jnarendr@yahoo.co.in.
authors.forename: Narendra K
authors.initials: NK
authors.lastname: Jain
mesh_terms: D000818:Animals; D004337:Drug Carriers / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D016679:Genome, Viral; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics / Q000502:physiology; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D004337:Drug Carriers; D034741:RNA, Small Interfering